- Home
- SDHY vs MREO Comparison
SDHY vs MREO Comparison
Compare SDHY & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- MREO
- Stock Information
- Founded
- SDHY 2020
- MREO 2015
- Country
- SDHY United States
- MREO United Kingdom
- Employees
- SDHY N/A
- MREO N/A
- Industry
- SDHY Finance/Investors Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SDHY Finance
- MREO Health Care
- Exchange
- SDHY Nasdaq
- MREO Nasdaq
- Market Cap
- SDHY 409.3M
- MREO 482.5M
- IPO Year
- SDHY N/A
- MREO N/A
- Fundamental
- Price
- SDHY $16.56
- MREO $2.85
- Analyst Decision
- SDHY
- MREO Strong Buy
- Analyst Count
- SDHY 0
- MREO 6
- Target Price
- SDHY N/A
- MREO $7.83
- AVG Volume (30 Days)
- SDHY 94.0K
- MREO 882.2K
- Earning Date
- SDHY 01-01-0001
- MREO 03-26-2025
- Dividend Yield
- SDHY 8.46%
- MREO N/A
- EPS Growth
- SDHY N/A
- MREO N/A
- EPS
- SDHY 1.07
- MREO N/A
- Revenue
- SDHY N/A
- MREO $1,000,000.00
- Revenue This Year
- SDHY N/A
- MREO N/A
- Revenue Next Year
- SDHY N/A
- MREO N/A
- P/E Ratio
- SDHY $14.31
- MREO N/A
- Revenue Growth
- SDHY N/A
- MREO N/A
- 52 Week Low
- SDHY $13.93
- MREO $2.53
- 52 Week High
- SDHY $15.50
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- SDHY 52.54
- MREO 38.17
- Support Level
- SDHY $16.51
- MREO $2.82
- Resistance Level
- SDHY $16.65
- MREO $2.99
- Average True Range (ATR)
- SDHY 0.10
- MREO 0.13
- MACD
- SDHY -0.01
- MREO 0.01
- Stochastic Oscillator
- SDHY 43.48
- MREO 14.74
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).